| Subject: | RECALL of Fluorouracil Injection, USP, 50 mg/mL, 500mg/10 mL Single Dose Vial |
| Category: | Food and Drug Administration (FDA)
|
| Published: | Thu, 29 Sep 2005 - 10:00 am |
| American Pharmaceutical Partners, Inc., (APP) has recalled all lots of Fluorouracil Injection, USP, 50 mg/mL, (500mg/10 mL Single Dose Vial), because of the potential for invisible glass particles to be present in vials of Fluorouracil Injection, USP, 50 mg/mL, (500mg/10 mL Single Dose Vial). These particles are composed of the glass constituents, silica and aluminum.
Only Product Code 101710 is susceptible to this type of glass breakdown. APP's other Fluorouracil product codes are... The full article is available to StayAlert subscribers. Click here for a free trial subscription. |
|
RESOURCES:
Customizable Documents and Tools:
Related MCN Products:
|
|
StayAlert! notifies healthcare customers of all federal and regulatory body legislation changes impacting the healthcare industry, including TJC (JCAHO), CDC, CMS, DHHS, FDA, OSHA, OIG and many others. StayAlert! complements this with regulatory implementation action plans. StayAlert! serves as a virtual healthcare department, augmenting traditional employee staffed departments and freeing employees to perform other vital functions. The StayAlert! system was designed by healthcare professionals actively working in the healthcare environment, who were faced with attempting to competently provide quality care and services while "doing more with less". StayAlert! provides the answer to efficiently performing a variety of required job components from one centralized virtual location. StayAlert! improves data sharing and communications, thus reducing cost, broadening access and providing a system of documentation and follow-up. |
|